Figure S1 from Targeting SALL4 with an HLA Class I–Restricted TCR for Cancer Immunotherapy

S9V is an immunogenic peptide in humanized mouse model. (A) The immunogenicity of SALL4-derived peptides (A9V, T9K, V9L, L10L, K9Y and S9V) has been analyzed in vivo in HLA-DRB1*0101/HLA-A*0201 (A2/DR1) humanized mouse model. These are "Knock Out" mice for murine MHC-I and II molecules. Hockpad immunization starts on day 0 with an injection of 100µg of each peptides and with 50µg of an adjuvant, CpG. Two further injections were performed on day 7 and day 14 with 50µg of each peptides and with 30µg of CpG. The mice were sacrificed on day 16 to harvest the popliteal lymph nodes and SALL4-specific immune responses were analyzed. (B) Representation of ex vivo T cell responses analyzed by murine IFN-γ ELISpot assay for one S9V positive mice. (C) Median intensities and (D) frequencies of SALL4-specific immune responses were assessed by IFN-γ ELISpot assay in popliteal lymph nodes of humanized mouse after hockpad immunization. Responses were considered positive when the IFN-γ spot number was ≥10 and the ratio was 2-fold above the background. Only the positive intensities of specific immune responses were indicated.